Click on headlines below to download research

Growth underpinned by international momentum
AFT Pharmaceuticals | 23/05/2024

AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven…

Maxigesic IV’s Brazil entry, a foray into LATAM
AFT Pharmaceuticals | 02/05/2024

AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South America…

Expanded R&D pipeline to fuel LT growth
AFT Pharmaceuticals | 29/04/2024

While AFT continues to gain commercial traction from Maxigesic/ Combogesic IV sales in the US (launched by partner Hikma in Q1 CY24) and anticipates the…